| By Linda Yao, Asia Manufacturing Pharma |
| Tuesday, 03 June 2008 |
 |
|
Asymchem Laboratories Inc., one of China’s leading contract manufacturers of pharmaceutical ingredients, recently held a ground breaking ceremony for its new plant, Asymchem Laboratories (Jilin) Co., Ltd. in Dunhua, Jilin province. Attendees included Dunhua party secretary Han Xinghai and several other local government officials as well as Dr. Hao Hong, chairman of the new plant. |
|
|
Located in the Dunhua Economic Development Zone, Jilin province, Asymchem Laboratories
(Jilin), with a total investment of RMB 240 million (approx. $US 34 million) and a total area of 220,000 square meters, will include an FDA-approved cGMP production facility, power center, material supply center and international advanced EHS control center, aiming to produce new and high-technology active pharmaceutical ingredients (APIs), intermediates and relevant basic materials on a large scale. The company will provide high quality products to distributors including the world’s ten leading pharmaceutical
|
|
|
companies.
The Phase I project covers a land area of approximately 100,000 square meters. A 20,000 square meters production facility designed to produce high quality cGMP and non-GMP basic materials and APIs, which will be completed soon, has been designed in accordance with international standards. The Phase I project is expected to be put into full production in early 2009. With an annual capacity of more than 30 tons, a production value of RMB1.5 billion (approx. $US 215 million) is expected to be realized in 3 years as part of the Phase I project. |
|
The new cGMP production base, which received its investment from Asymchem Laboratories (Tianjin) Co.,Ltd., will significantly improve Asymchem’s mass production ability and further enhance Asymchem’s position as a leading CMO and Contract Research Organization (CRO) provider in China after its completion. Two factors, self-sufficient basic materials and stable sales of APIs, can ensure the growth of Asymchem Laboratories (Jilin).
Dr. Hong emphasized during his speech at the ceremony that the new facility is expected to bring advanced management concepts and industry standards to Dunhua, while creating more employment opportunities for local residents.
______________________________
Want to read more?
______________________________
China's Active Pharmaceutical Inredients (APIs) prosperity may continue
China’s API exports expected to grow 20% in 2008
Outsourcing market boom to create significant opportunities for China’s API manufacturers
|
|
|
